中新网广州1月11日电 题：水利专家学者聚首广州 共探水生态环境提升之路 值得一提的是，该论坛的十一位专家学者报告聚焦水治理多维度关键议题，形成系统解决方案。其中， 流域治理层面，涵盖珠江水资源协同保护、下游水网动力重构及全球视野下的洪水管理，强化统一调度 与系统治理思维。城市水安全领域，聚焦极端暴雨应对与韧性提升，探索水体整治、面源污染防控等技 术路径。生态修复方面，关注幸福河湖建设、库区蓝藻防控及河湖水污染治理与水生植被恢复协同发 展。 分享环节中，水利部珠江水利委员会水资源节约与保护处处长张广燕聚焦《强化流域统一管理，协同保 护珠江水资源》；清华大学水利水电工程系教授、水圈科学与水利工程全国重点实验室城市韧性团队首 席科学家倪广恒带来了《极端暴雨下城市韧性提升及应急技术》；水生态环境部华南环境科学研究所正 高级工程师丘锦荣以《城市水体系统整治与监管》为题作报告。 此外，中国水利企业协会水环境治理分会会长周付春表示，该分会将继续发挥平台与智库作用，紧密围 绕"三水统筹"与幸福河湖建设，汇聚行业力量，推动技术创新与成果转化，助力会员单位及水环境治理 产业高质量发展。(完) 论坛现 场。论坛组委会 供图 中新 ...

《方案》明确，积极推进水生态保护修复，包括修复河湖生态缓冲带、保护水生生物、深化富营养 化治理，同时夯实水生态监测和监管基础。 在构建绿色发展机制上，《方案》明确巩固饮用水水源安全成效、完善水生态产品价值实现机制。 此外，从组织领导、资金投入、科技支撑、公众参与等方面制定保障措施，确保方案落地实施。 "我们组织开展省级美丽河湖优秀案例征集活动，选树一批省级美丽河湖优秀案例，从中择优申报 国家级美丽河湖优秀案例。同时，将加强水生态环境领域科技创新，强化关键技术研究，促进科技成果 转化应用，支持美丽河湖保护与建设。"省生态环境厅相关负责人表示。（记者：李欣泽） 1月6日，记者从省生态环境厅获悉：陕西近日印发《陕西省美丽河湖保护与建设实施方案（2025— 2027年）》，从水环境治理、水资源保障、水生态修复等多维度出台具体举措，为全省美丽河湖保护与 建设制定清晰路线图，通过构建长效机制全面推进河湖生态环境持续改善。 在持续推动水环境治理上，《方案》提出加快补齐城镇污水处理设施短板，2027年城市生活污水集 中收集率达73%；提升入河排污口监管水平，完成排查整治并建立常态化监管体系；深化工业园区水污 染防治，开展工业 ...

为贯彻落实中山市委、市政府打赢水污染治理攻坚战的重大决策部署，中山公用（000685）水环境治理 有限公司（以下简称"公司"）依托城区"厂网一体化"实践积淀，锚定非中心城区主战场，成功运营火炬 开发区（含民众街道）、三角镇厂网一体化项目，以系统治理、专业运营、智慧赋能为抓手，打造可复 制的镇街治水"公用样板"。 火炬开发区 从"快速启航"到"稳健运营" 多维突破彰显治理实效 火炬开发区厂网一体化项目是公司拓展镇街治水版图的标志性实践。2025年6月，中山公用与火炬开发 区属企业合资成立中山公用火炬水环境公司，以"提质增效、改善水质、保障防汛、智慧转型"为目标， 推动区域水环境治理跨越式突破，多项关键指标达标杆级水平。 污水收集效能跃升，夯实低碳运行根基。洋关污水处理厂聚焦外水入侵整治核心难题，中山港街道开展 拉网式排查，累计投入超2500人次，精准锁定146处外水点（日均外水4.1万方）。目前已完成41处点位 长效整治，片区污水收集率提升了35.52个百分点，超额完成市级目标；洋关污水处理厂进厂BOD平均 浓度同比提升34.17%，11月单月达84.3mg/L，"量增质升"成效显著。 河涌水质迭代升级，绘就生 ...

长荡湖是太湖流域重要的生态屏障，江苏省常州市金坛区立足"上游担当"，以新一轮洮滆片区水环境质 量提升攻坚年行动为总抓手，聚焦控源截污、生态修复、协同共治三大关键环节的"1+3"治水模式，精 准发力破解治水难题。2025年，金坛长荡湖平均水质首次达到Ⅲ类，相比2021年，水质跃升两个类别， 总磷指标下降60.6%，创"十四五"以来最好水平。 金坛长荡湖 "生态颜值"蝶变"发展产值"。金坛区充分发挥长荡湖秀水美景、湖鲜美食、历史美名等独特优势，重点 推进以生态环境为底色、科技创新为本色、休闲公园为特色的国家湿地公园、华罗庚科学城和休闲运动 公园等"一城两园"规划建设，生态红利持续释放，文旅产业蓬勃发展。 未来，金坛区将持续深化"1+3"治水模式，全力打造国家生态文明建设示范区、"两山"实践创新基地和 长荡湖"生态岛"试验区，让清水绿岸成为金坛永续发展的宝贵财富。 ...

"湖光山色"是杭州向全球递出的一张城市名片。 如今，这张名片的背后，有一组更硬核的数据支撑着：今年1月至10月，杭州市省控以上地表水断 面达到或优于Ⅲ类比例、水功能区达标率及县级以上集中式饮用水水源水质达标率，均达100%。 为了严防黑臭水体"返黑返臭"，杭州还建立起了动态排查整治机制，持续监控，确保治理成果不反 弹。今年以来，通过常态化巡查发现，将8个存在返黑返臭风险的点位纳入监管，并落实整改，将问题 消灭在萌芽状态。 "三个100%"，意味着杭州的主要河流湖泊水质稳定在优良水平，更意味着千万市民的饮水安全得 到了最高级别的保障。 碧水长流润杭城，背后是一场围绕"水"展开的、持续多年的系统治理与精心守护。 "五水共治" 一场关乎民生的系统工程 杭州的治水，核心在于"五水共治"——治污水、防洪水、排涝水、保供水、抓节水。这并非五个独 立的"战场"，而是环环相扣的有机整体。 水里的问题，根子在岸上。为了做好源头管控工作，杭州持续开展入河排污（海）口"查、测、 溯、治"工作，完成了第一轮市级巡查，对新发现的24个排污口问题均落实"一口一策"整治措施，从源 头削减入河污染负荷。 为确保城乡居民喝上干净水、放心水，杭 ...

Core Viewpoint - Company Jindalai (688057) is diversifying into the medical sector by investing in two companies focused on stem cell research and medical robotics, following a decline in its performance since its IPO. The market reacted positively to these announcements, with a stock price increase of over 11% on December 22 [1][4]. Investment Details - Jindalai plans to invest CNY 280 million in Yunnan Jici Medical Technology Co., acquiring a 34% stake, and CNY 30 million in Zhongke Hongtai Medical Technology Co., acquiring a 10% stake [3][4]. - Jici Medical specializes in autologous cell technology and has conducted safety and efficacy validations for over 30 clinical indications [3]. - Zhongke Hongtai focuses on medical robotics and has completed clinical trials for its vascular intervention surgery robot [3][4]. Financial Performance - Jindalai has faced declining revenues and profits since its IPO, with revenues dropping from CNY 9.71 billion in 2020 to CNY 4.09 billion in 2024, and net profits decreasing from CNY 3.87 billion to CNY 1.37 billion in the same period [9]. - For the first three quarters of 2024, Jindalai reported revenues of approximately CNY 236 million, a 23.5% year-on-year decline, and net profits of CNY 75 million, down 30.14% [9]. Risks and Concerns - Both target companies present financial risks: Zhongke Hongtai has not yet achieved profitability, while Jici Medical has negative net assets, indicating it is in a state of insolvency [6][7]. - The investments are made at a premium, with Jici Medical's valuation at CNY 544 million, raising concerns about the potential for future returns [8]. - The medical technology sector is characterized by high barriers to entry and significant R&D costs, which may pose challenges for Jindalai, a company primarily focused on environmental services [10].

Core Viewpoint - Jindalai, a water environment management company, is diversifying into the healthcare sector by investing in two medical technology firms, despite facing financial uncertainties in these target companies [1][5]. Group 1: Investment Details - Jindalai plans to invest CNY 280 million in Yunnan Jici Medical Technology Co., acquiring a 34% stake, focusing on autologous cell technology [2]. - The company will also invest CNY 30 million in Zhongke Hongtai Medical Technology Co., obtaining a 10% stake, which specializes in medical robotics [2]. - Both investments are seen as a strategic move to optimize Jindalai's industry structure and enhance its risk resilience [3]. Group 2: Financial Performance of Target Companies - Zhongke Hongtai reported revenues of approximately CNY 132,100 and CNY 102,600 for the last year and the first three quarters of this year, respectively, with net losses of CNY 11.4 million and CNY 5.5 million [5]. - Jici Medical's revenues were CNY 8.69 million and CNY 11.23 million for the same periods, with net profits of CNY 2.23 million and CNY 1.15 million [5]. - As of the end of Q3 this year, Jici Medical had negative net assets of CNY 31.53 million, indicating a state of insolvency [5]. Group 3: Valuation and Risks - The investments are made at a premium, with Jici Medical's assessed value at CNY 544 million, primarily due to the value of its patents and ongoing projects [6]. - The success of Jici Medical's business and financial outlook heavily relies on the successful clinical development and commercialization of its drug candidates [6].

Core Viewpoint - Company Jindalai (688057) is diversifying into the medical sector by investing in two companies focused on stem cell research and medical robotics, despite facing declining performance in its core water treatment business since its IPO [1][10]. Investment Details - Jindalai plans to invest CNY 280 million in Yunnan Jici Medical Technology Co., acquiring a 34% stake, which focuses on the development and application of autologous cell technology [4]. - The company also intends to invest CNY 30 million in Zhongke Hongtai Medical Technology Co., obtaining a 10% stake, which specializes in medical robotics [4]. - Both investments are seen as cross-industry moves for Jindalai, which has traditionally focused on water environment management [5]. Financial Performance - Jindalai has experienced a decline in revenue and net profit for four consecutive years since its IPO, with revenues dropping from CNY 9.71 billion in 2020 to CNY 4.09 billion in 2024 [11]. - In the first three quarters of 2024, Jindalai reported revenues of approximately CNY 236 million, a year-on-year decrease of 23.5%, and a net profit of CNY 75 million, down 30.14% [11]. Risks and Concerns - Both target companies present financial risks: Zhongke Hongtai has not yet achieved profitability, while Jici Medical has negative net assets, indicating a state of insolvency [7][8]. - The investments are made at a premium, with Jici Medical's assessed value at CNY 5.44 billion, raising concerns about the potential for future returns [9]. - The medical technology sector is characterized by high barriers to entry and significant R&D costs, which may pose challenges for Jindalai, a company lacking experience in this field [12].

Core Viewpoint - The newly implemented "Management Measures for Incentive Compensation Funds for River Water Quality in Liaoning Province" aims to enhance and standardize fund management, improve fund utilization efficiency, and promote the long-term mechanism for river water quality incentive compensation in the province [1] Group 1: Changes in Fund Management - The new regulations shift from a "one-way" compensation system to a "two-way" flow of funds, allowing for compensation and incentives based on pollution and improvement between upstream and downstream areas [2] - The scope of provincial funding support has been expanded to include not only compensation for downstream polluted cities but also incentives for improvements in inter-provincial rivers and cross-border rivers [2] - The new measures implement a "tiered" management mechanism for incentive recipients, increasing incentives for cities that show annual water quality improvements, moving away from a "universal" approach [2] Group 2: Enforcement and Oversight - The Liaoning Provincial Finance Department will collaborate with the Provincial Ecological Environment Department to ensure strict implementation of the new fund management measures and enhance performance management of funds [3] - There will be stringent supervision and performance management, with penalties for projects that are significantly delayed or where funds are idle or ineffective, establishing a system where funding is determined by actual effectiveness [2][3]

Core Viewpoint - Company plans to invest 30 million yuan in Zhongke Hongtai to acquire a 10% stake, aiming to optimize its industrial structure and explore new growth opportunities in the medical robotics sector [2] Group 1: Investment Details - The investment is based on the positive outlook for the development of medical robotics technology and applications in strategic emerging industries [2] - The investment will enhance the company's risk resistance and cultivate new profit growth points [2] Group 2: Zhongke Hongtai Overview - Zhongke Hongtai specializes in the research, production, and sales of medical robotics technology and systems, being a technology transfer enterprise incubated by the Chinese Academy of Sciences [2] - The founding team has undertaken over 10 major projects, including the first domestic "863 Program" for vascular interventional surgical robots since 2008, establishing itself as a pioneer in the field [2] - The company holds over 100 independent intellectual property rights and has participated in the formulation of 2 industry standards [2] Group 3: Product Advantages - Zhongke Hongtai's multi-channel vascular interventional surgical robot features bionic design, allowing simultaneous rotation and pushing of guidewires, and can operate two guidewires and two balloon/stent catheters simultaneously [3] - The robot includes force feedback functionality and can perform remote surgeries, full-process robotic assistance, and data collection [3] Group 4: Clinical Trials and Future Plans - The product requires clinical trials before market registration, with the first patient enrolled in a clinical trial for the world's first multi-channel fully assisted vascular interventional surgical robot on November 25, 2025 [3] - As of the announcement date, 16 clinical trials have been completed, and the company is accelerating progress [3] Group 5: Company Strategy - The company is an advanced innovative comprehensive service provider for water environment governance and plans to invest in non-listed companies in the health sector, including medical devices and biomanufacturing, to optimize its industrial structure [2][3]